Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Castle Biosciences’ genomic tests for melanoma, ophthalmology and gastroenterology come with layers of clinical trial data, reimbursement disclosures and risk factors. Finding the impact of a new Medicare rule or evaluating pipeline milestones inside a 300-page report can feel overwhelming.
Our platform solves that problem. Stock Titan’s AI reads every Castle Biosciences SEC filing the moment it hits EDGAR and delivers plain-English answers. Whether you need the Castle Biosciences quarterly earnings report 10-Q filing for revenue-per-test trends or want Castle Biosciences insider trading Form 4 transactions before the market opens, the information is distilled into concise summaries, key metrics and red-flag alerts.
- AI highlights reimbursement commentary buried in the Castle Biosciences annual report 10-K simplified.
- Real-time alerts surface Castle Biosciences Form 4 insider transactions real-time so you can track executive sentiment.
- One-click access to the Castle Biosciences proxy statement executive compensation helps you benchmark management incentives.
- Need context on FDA news? The platform provides Castle Biosciences 8-K material events explained in seconds.
Because our AI understands oncology terminology, understanding Castle Biosciences SEC documents with AI becomes straightforward. Use the built-in tools for Castle Biosciences earnings report filing analysis, compare segment margins, or export data tables to your model—no manual copy-and-paste.
From Castle Biosciences SEC filings explained simply to tracking Castle Biosciences executive stock transactions Form 4, this page is your complete, continuously updated resource for every 10-K, 10-Q, 8-K, S-8 and beyond.
Castle Biosciences (CSTL) disclosed a proposed sale of 43,019 common shares through Goldman Sachs & Co. LLC with an aggregate market value of $834,998.79. The form lists the approximate date of sale as 08/13/2025 and identifies the securities exchange as NASD. The shares were recorded as acquired on 08/08/2025 from the issuer as performance award compensation, with payment dated 08/08/2025. The filing also reports multiple related-party sales on 06/27/2025 by The Maetzold trusts and Derek Maetzold totaling specific share amounts and gross proceeds. The filer certifies compliance with Rule 144 and affirms no undisclosed material adverse information.
Derek Maetzold, President & CEO and a director of Castle Biosciences (CSTL), reported the conversion of 66,991 performance-based stock units into common shares and a sale of 23,972 shares at $19.36 on 08/08/2025. After the reported sale his direct beneficial ownership is shown as 112,702 shares. The filing documents trust movements on July 11, 2025 (transfers into his direct holdings) and July 14, 2025 (transfer of 44,323 shares from his direct holdings to a grantor retained annuity trust). The PSUs converted represent the remaining 50% of a December 23, 2022 grant that vested in full on the one-year anniversary of August 9, 2024.
Frank Stokes, Chief Financial Officer of Castle Biosciences (CSTL), reported both an issuance and a sale of company stock on 08/08/2025. He received 9,744 shares through the settlement of performance-based stock units (PSUs) at no cash cost; those PSUs are described as the remaining 50% of PSUs granted on December 23, 2022 that vested in full on the one-year anniversary of August 9, 2024. The filing also discloses a sale of 4,356 shares at $19.36 per share.
The filing lists beneficial ownership amounts of 53,072 shares following the acquisition and 48,716 shares following the sale. Based on the reported numbers, Stokes' holdings increased by 5,388 shares net (9,744 acquired minus 4,356 sold). The transactions are reported on a Form 4 filed by the reporting officer.
Kristen M. Oelschlager, Chief Operating Officer and Director of Castle Biosciences, Inc. (CSTL), reported transactions on 08/08/2025 on a Form 4. The filing shows an acquisition of 10,640 shares of common stock at a reported price of $0, and a disposition of 2,804 shares at $19.36 per share. The filing records 171,800 shares beneficially owned following the reported transactions. Table II and the explanation state these 10,640 units relate to Performance-Based Stock Units (PSUs), each representing one share; the PSUs comprised the remaining 50% of a grant made on December 23, 2022, which vested on August 9, 2024.
Castle Biosciences insider activity: The reporting person, Tobin W. Juvenal (Chief Commercial Officer), reported acquisition and disposition of common stock on 08/08/2025. He acquired 10,640 shares through performance-based stock units (PSUs) at $0 and disposed of 4,294 shares at $19.36. The PSUs are described as representing one share each and constitute the remaining 50% of a grant from December 23, 2022, which vested on August 9, 2024.
After the reported transactions the form shows 84,527 shares directly beneficially owned and 2,230 shares held indirectly by the Tobin W. and Susan M. Juvenal Family Revocable Trust. The report was submitted on behalf of the reporting person by an attorney-in-fact.
On August 5, 2025, Castle Biosciences, Inc. adopted amended and restated bylaws effective the same date. The A&R Bylaws revise stockholder nomination and advance-notice procedures by requiring nominees to be stockholders of record at the annual meeting, expanding disclosure and certification obligations for proponents and nominees, limiting the number of stockholder-submitted nominees to the number of directors up for election, and incorporating the Rule 14a-19 universal proxy requirements. The bylaws change meeting mechanics by setting quorum as a majority of voting power, making approval the majority of votes cast (excluding abstentions and broker non-votes), adjusting the annual-meeting alternative window (applies if advanced by more than 30 days or delayed by more than 70 days), and clarifying special meeting procedures. Other amendments update indemnification and expense-advancement provisions, refer to the certificate of incorporation for certain determinations, and require the full A&R Bylaws be filed as Exhibit 3.1.
Castle Biosciences, Inc. (CSTL) – Form 144 overview
The filing reports a proposed sale of 16,932 common shares by insider-related entities, to be executed through Goldman Sachs & Co. LLC around 27 June 2025. At the most recent share count disclosed in the notice (28,872,315 shares outstanding), the planned disposition represents roughly 0.06 % of total shares, indicating a limited potential impact on the public float.
Historical sales disclosed for the preceding three months total 11,288 shares spread across multiple Maetzold family trusts, yielding aggregate gross proceeds of approximately $226,000 (sum of line-item figures). No additional company financial metrics, earnings data, or operational updates are provided in this Form 144.
Key takeaways for investors
- The filing signals continual, but small-scale, insider selling activity.
- Because the quantity is less than 0.1 % of shares outstanding, market impact is expected to be minimal under normal trading volumes.
- No mention is made of a Rule 10b5-1 trading plan; however, the signee affirms lack of undisclosed material adverse information as required by Rule 144.
Overall, the notice is routine and does not, on its own, imply any change in Castle Biosciences’ fundamentals or forward outlook.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
